Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
NEW YORK (TheStreet) -- Has the market gotten too complacent about these new highs? Jim Cramer told his Mad Money viewers Friday he thinks that might be the case, and next week's game plan will be a difficult road for the bulls.
Cramer said the markets will be ruled by two macro-economic events next week -- the European Central Bank's decision on interest rates on Thursday and the U.S. non-farm payroll numbers on Friday. Whatever stocks may gain earlier in the week can be easily be undone by these two events.
Then there's the Apple (AAPL) Worldwide Developers Conference that kicks off on Monday. Cramer said this stock, which he owns for his charitable trust, Action Alerts PLUS, has created 300,000 jobs in the burgeoning app economy and this conference should help buoy the markets.Then, on Tuesday, Cramer said he'll be watching Dollar General (DG). While he generally likes the dollar group, Cramer said he'd bet on Target (TGT) with its 3% yield and its new CEO. Wednesday brings earnings from Brown-Forman (BFB) and PVH Corp (PVH). Cramer said he'd be a buyer of Forman but would take profits and lock in gains with PVH because the stock has had a nice move higher. On Thursday, J.M. Smucker (SJM), Ciena (CIEN), Joy Global (JOY) and Zoe's Kitchen (ZOES) will all be reporting. Cramer said he wants to hear Smucker's thoughts on the recent wave of consolidation in the food stocks, but he'd avoid Joy Global. He was also not a fan of Ciena, preferring Cisco Systems (CSCO), but does approve of owning Zoe's over the long term.
Executive Decision: Tom PikeFor his "Executive Decision" segment, Cramer sat down with Tom Pike, CEO of Quintiles Transnational (Q - Get Report), the company biotech firms turn to when they need to outsource their clinical trials. Quintiles just posted a 13-cents-a-share earnings beat on an 8.4% rise in revenue. Pike said it's been an exciting year for Quintiles. He said there has been a ton of money flowing into biotech firms and that means more drugs that need testing and more business for Quintiles.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts